Description and Brand Names
Drug information provided by: Merative, Micromedex®
US Brand Name
- Trodelvy
Descriptions
Sacituzumab govitecan-hziy injection is used to treat triple-negative breast cancer that has spread (metastatic) or cannot be removed by surgery (unresectable locally advanced). It is given to patients who have received 2 or more cancer treatments, including at least 1 treatment for metastatic disease.
Sacituzumab govitecan-hziy injection is also used to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread (metastatic) or cannot be removed by surgery (unresectable locally advanced) in patients who have received endocrine treatment and at least 2 treatments for metastatic disease.
Sacituzumab govitecan-hziy injection is also used to treat urothelial cancer (bladder cancer and cancer of the urinary tract) that has spread or cannot be removed by surgery in patients who have received other cancer medicines (eg, immunotherapy medicine, platinum-containing cancer medicine).
Sacituzumab govitecan-hziy belongs to the group of medicines called antineoplastics (cancer medicines). It interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells may also be affected by the medicine, other effects may also occur. Some of these may be serious and must be reported to your doctor.
This medicine is to be given only by or under the immediate supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: Feb. 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.